Loading clinical trials...
Loading clinical trials...
An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa
Pharmacokinetic (PK) study to characterize changes in serum concentrations in epilepsy patients when switching from LAMICTAL immediate-release to extended-release and vice versa.
Age
13 - No limit years
Sex
ALL
Healthy Volunteers
No
GSK Investigational Site
Anniston, Alabama, United States
GSK Investigational Site
Sun City, Arizona, United States
GSK Investigational Site
Lexington, Kentucky, United States
GSK Investigational Site
Lexington, Kentucky, United States
GSK Investigational Site
Boston, Massachusetts, United States
GSK Investigational Site
Reno, Nevada, United States
GSK Investigational Site
New York, New York, United States
GSK Investigational Site
Toledo, Ohio, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Nashville, Tennessee, United States
Start Date
October 1, 2005
Primary Completion Date
June 1, 2006
Completion Date
June 1, 2006
Last Updated
September 23, 2016
45
Estimated participants
lamotrigine extended-release
DRUG
Lead Sponsor
GlaxoSmithKline
NCT06700356
NCT02531880
NCT05871372
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions